FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

"This technology gives us a powerful tool to detect prostate cancer earlier and more precisely,” said Dr. James Howard.

A “search and destroy” treatment has been found to halt tumours in some men with incurable prostate cancer. The early-stage ...

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...

Over the past decade or so, prostate-specific membrane antigen (PSMA) PET/CT has increasingly replaced conventional imaging in men with biochemical recurrence after radical prostatectomy. PSMA PET/CT ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

Source: Getty Images The molecular imaging modality detects metastases earlier and more accurately compared with conventional imaging and has ushered in a new era in metastasis-directed therapy. PSMA ...

PSMA-PET imaging has higher sensitivity than conventional imaging and can detect radiorecurrent prostate cancer at lower PSA levels. PSMA-PET imaging can detect radiorecurrent prostate cancer lesions ...

The ongoing Daro-PET study set out to evaluate the ability of the oral androgen receptor inhibitor darolutamide (Nubeqa) to ...

MyMichigan Medical Center Sault has begun offering PSMA PET scans, providing men in the eastern Upper Peninsula with an advanced imaging tool to detect prostate cancer.

Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...

Clinical node involvement on preoperative PSMA-PET predicts radiographic recurrence for pN1 prostate cancer patients following RP/PLND.